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SUMMARY – The relationship between aging and changes in  heart rate variability (HRV) could 
depend on the metabolic profile of obese people, i.e. metabolically healthy obese (MHO) and meta-
bolically unhealthy obese (MUO). We aimed to determine the age at which obesity related auto-
nomic dysfunction becomes significant and whether it decreases differently according to metabolic 
profile. We analyzed HRV in 99 adults using Wildman’s criteria for metabolic profile and 5-minute 
HRV for autonomic nervous system. In MHO, high frequency (HF) decreased in the 4th decade of 
life. In MUO, standard deviation of R-R intervals (SDNN), root mean square of successive differ-
ences of all R-R intervals (RMSSD), number of adjacent intervals differing by more than 50 ms 
 expressed as percentage of all intervals in the collecting period (pNN50), HF, low frequency (LF), LF/
HF (LF divided by HF) and total power (TP) decreased in the 4th decade of life (partial shared 
 variance 28%-36%). In conclusion, an age dependent decrease of HRV occurs in MUO between the 
third and fifth decade of life. In MHO, HF significantly decreases around the age of 40 years. Cardio-
metabolic profile influences metabolic aging, altering the autonomic nervous system.
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Introduction
Analyzing obese people reveals that besides those 
with cardiometabolic risk (metabolically unhealthy 
obese (MUO) people) there are metabolically healthy 
obese (MHO), people who have a higher level of insu-
lin sensitivity, normal values of arterial blood pressure 
and a desirable lipid profile1. It is not clear whether 
MHO people are protected from the risk of chronic 
diseases allied with obesity, or it is a question of delay 
in the progression of complications in this subpopula-
tion of obese people2. It is considered that the auto-
nomic nervous system (ANS) has a role in these differ-
ent outcomes3. ANS alterations can even be spotted in 
childhood obesity4.
Abnormal autonomic regulation, estimated through 
heart rate variability (HRV), is ever more cited as a link 
between metabolic disorders and cardiovascular events. 
Lower HRV is a risk factor for mortality and it precedes 
the appearance of many modifiable and non-modifiable 
risk factors for the development of cardiovascular dis-
eases5. The connection between obesity and low para-
sympathetic activity estimated through HRV is found 
in the early period of life4. Autonomic functions, esti-
mated through HRV, decline with age6.
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We wanted to examine at what age in the continu-
um of metabolic changes in obese people, cardiac ANS 
activity changes. We hypothesized that, depending on 
the metabolic profile, there are differences in the age at 
which HRV decline appears. Higher HRV has been 
found in MHO compared to MUO people7,8. It would 
be of great interest to evaluate how the connection of 
cardiac-autonomic and cardio-metabolic functions in-
teracts with the aging process in obese people.
Subjects and Methods
This cross-sectional study group included 99 obese 
people, 36 men and 63 women (body mass index (BMI) 
≥30 kg/m2), age range 19-61 (mean age 41.28±12.15) 
years, attending general practice in Novi Kneževac and 
Novi Sad during the 2013-2014 period. There were 43 
premenopausal and 21 postmenopausal women. Exclu-
sion criteria were pregnancy, smoking, alcohol con-
sumption, use of hormone replacement therapy, use of 
chronotropically active medications, having an implant-
able pacemaker, active infection, thyroid-, adrenal- and 
inflammatory disease. Postmenopausal status was de-
fined as the absence of menstrual cycle in the past one 
year. The study was approved by authorities in each 
study centre, as well as by the Ethics Committee. All 
subjects provided their signed voluntary informed con-
sent. The study was conducted in accordance with the 
Declaration of  Helsinki.
Body weight was measured using a balanced beam 
scale to the nearest 0.1 kg. Body height was measured 
using Harpenden anthropometer (Holtain Ltd., Cro-
swell, UK) to the nearest 0.1 cm. BMI was calculated 
as a quotient of weight in kilograms and squared body 
height in meters. Blood pressure was measured after 
5-minute rest on the left arm using Riva-Roccy sphyg-
momanometer. Total cholesterol and triglyceride levels 
were determined by the standard enzyme-based meth-
od. High-density lipoprotein (HDL)-cholesterol lev-
els were determined by the precipitation method with 
sodium phospho-wolframate. Fasting glucose level 
was determined by the Dialab glucose GOD-PAP 
method. Serum insulin level was determined by 
ECLIA. The homeostasis model assessment of insulin 
resistance (HOMA-IR) was calculated as fasting glu-
cose (mmol/L) x fasting insulin level (mIU/L)/22.5. 
The high-sensitivity C-reactive protein (hsCRP) was 
measured by latex enhanced nephelometry.
Metabolic profile was defined by the Wildman’s 
criteria. Wildman’s criteria for MHO were BMI ≥30 
kg/m2 and less than two or more of the following car-
diometabolic abnormalities: blood pressure level 
≥130/85 mm Hg or antihypertensive medication us-
age, elevated fasting triglyceride level (≥1.7 mmol/L), 
decreased HDL-cholesterol (<1.3 mmol/L for women 
and <1.04 mmol/L for men), elevated fasting glucose 
level (≥5.5 mmol/L) or antidiabetic medication usage, 
insulin resistance (HOMA-IR >5.8, 90th percentile) 
and systemic inflammation (CRP ≥10.28 mg/L, 90th 
percentile)9.
After 10 minutes of accommodation, 5-minute 
digital electrocardiography was recorded in sitting po-
sition (VNS-Spektr, Neurosoft, Ivanovo, Russia). A 
sampling rate of 1000 Hz was chosen and recordings 
were transferred to a computer. The epochs gained 
from the DII lead were saved in the computer for fur-
ther analysis. After automated R wave identification, 
all R-R intervals were edited by visual inspection to 
exclude any undesirable or ectopic beats. They were 
deleted with the post extra systolic beat and replaced 
automatically with interpolated adjacent R-R interval 
values. Patients where arrhythmia was detected were 
excluded from the investigation. Time and frequency-
domain analysis was performed. The following param-
eters were calculated: mean duration of all normal R-R 
intervals (RRNN; ms); standard deviation of R-R in-
tervals (SDNN); root mean square of successive differ-
ences of all R-R intervals (RMSSD); and number of 
adjacent intervals differing by more than 50 ms ex-
pressed as percentage of all intervals in the collecting 
period (pNN50). Frequency domain measures of HRV 
were derived by fast Fourier transformation: low-fre-
quency (LF; 0.04-0.15 Hz), high-frequency (HF; 
0.15-0.40 Hz) spectral power and total spectral power 
(TP; 0- 0.4 Hz). LFnorm and HFnorm are normal-
ized low and high frequencies expressed in normalized 
units, representing the relative values of each power 
component in proportion to total power minus very 
low frequency (VLF) component10. RRNN, SDNN 
and TP demonstrate overall HRV, both vagal and 
sympathetic influences; RMSSD, pNN50 and HF 
correspond to parasympathetic activity; LF represents 
sympathetic activity; and LF/HF indicates sympa-
thovagal balance10.
Data were analyzed using the SPSS 11.5 for Win-
dows software. Student’s t-test was used to show differ-
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ences in age and HRV variables between MHO and 
MUO. Data that did not have normal distribution were 
logarithmically transformed (ln). These were pNN50 
and TP in MHO, and pNN50 and LF/HF in MUO. 
One-factor analysis of variance was used to examine 
whether there were statistically significant differences in 
HRV markers among different age categories in both 
MHO and MUO subjects. In cases where variables 
were not homogeneous, the Welch statistics was used.
Results
Table 1 shows the mean values and standard devia-
tion of cardiometabolic factors and HRV markers in 
MHO and MUO men and women included in the 
study. Table 2 presents HRV marker differences in age 
subgroups of MHO subjects.
In the MHO subgroup, none of the subjects was in 
the 60-64 age group, so this category was excluded from 
analysis. In the MHO age groups, a statistically signifi-
cant difference was only recorded for HF; the youngest 
group had the highest HF marker, while the oldest 
group had the lowest HF. The most significant decrease 
in HF was found between 19-29 and 30-39 years of age 
(right after the period of 19-29 years of age).
In the MUO subgroup, HRV-age subgroup differ-
ences were found in SDNN, RMSSD, lnpNN50, 
lnLF, lnHF and TP (Table 3). The size of the effects 
Table 1. Age, cardiometabolic and cardiac-autonomic markers in MHO and MUO subjects
 MHO men MHO women MUO men MUO women
 N=15 N=31 N=21 N=32
 χ SD χ SD χ SD χ SD
Age (yrs) 38.07 9.38 38.94 10.92 41.52 13.35 44.91 12.51
Systolic BP (mm Hg) 123 17.71 117.39 17.91 133.81 14.82 136.56 17.06
Diastolic BP (mm Hg) 79.6 14.05 75.65 12.37 84.81 11.91 85.16 14.17
Total chol (mmol/L) 4.77 1.03 5.4 1.26 5.28 1.25 5.52 1.04
TG (mmol/L) 1.62 0.77 1.2 0.45 2.16 0.98 2.01 1.05
HDLchol (mmol/L) 1.2 0.27 1.59 0.4 1.12 0.28 1.39 0.24
Glycemia (mmol/L) 5.03 0.46 5.05 0.53 6.08 2.05 5.94 1.32
Insulin (mIU/L) 10.03 2.69 9.97 4.64 14.74 9.76 11.59 6.62
CRP (mg/L) 2.43 1.85 4.68 2.95 4.48 5.13 5.42 5.69
HOMA 2.22 0.53 2.24 1.06 3.98 2.93 3.06 1.96
BMI (kg/m2) 33.12 2.41 33.95 3.69 35.91 4.22 37.02 4.07
RRNN (ms) 867.93 151.925 851.97 94.261 827 148.144 807.91 97.638
SDNN (ms) 41.67 15.065 48.58 18.523 39.33 17.693 36.69 15.831
RMSSD (ms) 31.6 18.438 40.77 21.261 27.76 17.972 27.09 16.288
pNN50 (%) 13.39 16.651 18.74 17.149 9.21 12.9 7.39 11.36
LF (ms2) 779.87 805.405 814.19 664.237 731.21 767.456 495.29 475.462
HF (ms2) 432.77 335.96 793 699.116 530.51 657.175 375.56 482.967
LF/HF 2.34 1.438 1.41 0.939 2.21 1.684 1.48 0.997
TP (ms2) 2912.67 2179.939 2854.06 2051.474 2157.71 1932.227 1739.5 1291.665
LFnorm (nu) 64.02 16.511 53.43 14.337 62.73 13.968 56.7 13.226
HFnorm (nu) 35.98 16.511 46.57 14.337 37.27 13.968 43.3 13.226
MHO = metabolically healthy obese; MUO = metabolically unhealthy obese; BP = blood pressure; Total chol = total cholesterol; TG = 
triglycerides; HDLchol = high-density lipoprotein cholesterol; CRP = C-reactive protein; HOMA = index of insulin resistance; BMI = 
body mass index; HRV = heart rate variability; HF = high frequencies; LF = low frequencies; LFnorm = normalized low frequencies; HF-
norm = normalized high frequencies; LF/HF = ratio of low to high frequencies; pNN50 = proportion of interval differences of successive 
normal-to-normal intervals greater than 50 ms; TP = total power; RMSSD = square root of the mean of the sum of the squares of differ-
ences between adjacent normal-to-normal intervals; RRNN = mean duration of all normal R-R intervals; SDNN = standard deviation of 
normal-to-normal intervals; χ = mean; SD = standard deviation
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Table 2. HRV markers in age categories of MHO subjects
Dependent variable F df1 df2 p Part η² Difference between groups
b
Age (years) M Diff.c




















HF 3.270a 3 20.217 0.005 0.197 19-29 1115.10 A
30-39 731.88 A. B
40-49 471.28 B
50-59 350.08 B
















aWelch test; bLSD test; cgroups that do not share the same letter differ (diff.- difference)
F = ANOVA test; p = level of statistical significance; Part η² = partial shared variance; HRV = heart rate variability; MHO = metabolically 
healthy obese; HF = high frequencies; LF = low frequencies; LFnorm = normalized low frequencies; HFnorm = normalized high frequen-
cies; LF/HF = ratio of low to high frequencies; lnpNN50 = logarithmically transformed proportion of interval differences of successive 
normal-to-normal intervals greater than 50 ms; lnTP = logarithmically transformed total power; RMSSD = square root of the mean of the 
sum of the squares of differences between adjacent normal-to-normal intervals; RRNN = mean duration of all normal R-R intervals; 
SDNN = standard deviation of normal-to-normal intervals
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Table 3. HRV in age categories of MUO subjects
Dependent variable F df1 df2 p Part η² Group difference
a
Age (yrs) M Diff.b










RMSSD 4.912 4 0.002 0.290 19-29 44.13 A
30-39 32.38 A. C
40-49 18.56 B
50-59 20.18 B
60-64 21.11 B. C



































aLSD test; bgroups that do not share the same letter differ (diff.-difference); F-ANOVA test
p = level of statistical significance; Part η² = partial shared variance; HRV = heart rate variability; MUO = metabolically unhealthy obese 
people; lnHF = logarithmically transformed high frequencies; lnLF = logarithmically transformed low frequencies; LFnorm = normalized 
low frequencies; HFnorm = normalized high frequencies; lnLF/HF = logarithmically transformed ratio of low to high frequencies; 
lnpNN50 = logarithmically transformed proportion of interval differences of successive normal-to-normal intervals greater than 50 ms; TP 
= total power; RMSSD = square root of the mean of the sum of the squares of differences between adjacent normal-to-normal intervals; 
RRNN = mean duration of all normal R-R intervals; SDNN = standard deviation of normal-to-normal intervals
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ranged from 28% to 36% (around 30% of variance of 
difference in HRV marker could be attributed to age 
difference). Practically in each case, the youngest cat-
egory had the highest scores, which decreased with 
increasing age, up to the age category of 40-49 years. 
After this category, the results were in stagnation. The 
most significant decrease in HRV markers occurred 
between 19-29 and 40-49 years of age. Only in case of 
variable RMSSD, the age category of 30-39 years did 
not differ from the age category of 60-64 years. It is 
interesting that in MUO, HRV differences between 
age categories had relatively large effects. In each case, 
except for lnLF/HF, LFnorm and HFnorm, the size of 
the effect was around 30%. The results indicated that 
differences in age categories of HRV were more prom-
inent and significant in MUO as compared to MHO 
subjects.
Discussion
Lower HRV is independently associated with lipid 
metabolism derangement, poor glycemic uptake, coro-
nary heart disease, myocardial infarction, and above all, 
mortality11. It is surely possible that ANS is included 
in the cascade of dysmetabolic events which allies cen-
tral obesity with insulin resistance12. Central place in 
cardiac autonomic neuropathy belongs to the impaired 
glycemic control11. Other contributing factors are age, 
obesity, nephropathy, peripheral neuropathy, retinopa-
thy, hypertension and smoking11. We found HRV to 
decrease with age, precisely in the fourth decade of life 
in MUO subjects. In MHO subjects, the decade of 
life-related decrease in HRV measures was not statis-
tically significant, except for significant differences in 
HF marker. In our study, age correlated significantly 
negatively with RMSSD, LF and TP in men and with 
all HRV measures in women (not shown in tables), 
supporting previous reports on HRV decline with 
age6. HRV differences between MHO and MUO sub-
jects are statistically significantly influenced by age8. 
Lower HRV is more closely connected to the meta-
bolic risk in obese individuals with increasing age8. It 
has been shown that HRV is reduced in women com-
pared to men with the same nutritional level6,13. In 
contrast to this, in our investigation MHO women 
had higher HFnorm and lower LF/HF and LFnorm 
compared to MHO men, while in MUO subjects 
there were no sex differences in HRV markers (not 
shown in tables). Tendency of HRV decrease in female 
is connected to lowering of the estrogen level in meno-
pause14. Unlike women, men do not experience sudden 
decline in sex hormones during aging15.
Reduced HRV is connected to the higher level of 
obesity16, hypertension, coronary heart disease, diabe-
tes, hyperlipidemia, and other components of meta-
bolic syndrome17. There were no differences in nutri-
tional level and age between men and women (not 
shown in tables).
Lower HRV has been established as an indepen-
dent predictor of elderly people mortality18,19. Central 
obesity in adolescents correlates with change in cardiac 
autonomic control, suggesting that impairment in car-
diovascular system begins in childhood20. Gutin et al. 
suggest that, concerning the fact that HRV decreases 
from 10th to 99th year of life, life habits that can help 
the child develop higher levels of HRV at an early age 
could preserve higher HRV at an older age and slow 
down some aspects of the aging process19. Our results 
are in line with this, supporting the necessity of pre-
serving appropriate metabolic profile in order to slow 
down the autonomic aspect of aging. Also, we high-
light the age period when this ANS deprivation could 
start. It is hard to preserve increment of HRV, but dec-
rement could be prevented with healthy lifestyle. 
Based on their results, Uusitalo et al. concluded that in 
the disease group, modifiable and lifestyle factors in-
fluenced autonomic balance more than genetic factors 
and that changeable factors, including anthropometric 
factors, could be the main factors in LF/HF change in 
diseased twins18.
Association of fat mass distribution to cardiac au-
tonomic nervous activity is not independent and could 
be attributed to the aging process8. Lower sympathetic 
activity in central fat mass21 allied with tendency of 
visceral fat mass towards insulin resistance, with aging 
allows further fat mass expansion in the central re-
gion22. This, in turn, leads to the age dependent decline 
in autonomic activities22.
Aging process is characterized by progressive de-
privation in physiological functions, leading to a high-
er risk of diseases, especially cardiovascular. There is a 
global tendency of human aging. Age is one of the 
most important correlates with autonomic nervous 
functions, as also confirmed in this study. HF decreas-
es with age, independently of sex23. In our study, HF 
was the only marker that differed between age groups 
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in MHO. Decreasing trend of HF was significant in 
the period between third and fifth decade of life. In 
MUO, most of HRV measures showed a statistically 
significant decline between third and fifth decade of 
life.
Uusitalo et al. report that age has significant effects 
on HRV, except for LF/HF18. Since in our study, 
MHO women differed from men in LF/HF (not 
shown in tables), we did not interpret this marker in 
the analysis of HRV differences among age subgroups 
Still, MUO age groups did not differ in LF/HF.
Some researchers used 24-hour HRV, others used 
5-minute HRV. In both cases, results are the same 
concerning age, demonstrating age to have direct neg-
ative effect on HRV17. Based on our results, this im-
pact of age appeared to be more pronounced in MUO 
subjects, leading to a more prominent HRV depriva-
tion. Parasympathetic modulation in MHO changed 
and decreased during fourth decade of life. In MUO, 
both sympathetic and parasympathetic heart modula-
tions decreased during fourth decade of life. In older 
age, there was stagnation of HRV levels in MUO 
(starting from 40-49 years of life), pointing to the es-
sential need for earlier prevention of HRV derange-
ment. The most dramatic fall in HRV could be seen 
between age 19-29 and 40-49.
In mice, the increasing number of neuron-specific 
substrates for insulin receptors leads to lowering of the 
locomotive activity, enlargement of fat mass, insulin 
resistance and glucose intolerance allied with age24. 
Obesity and its complications such as insulin resis-
tance provoke autoimmune reactions, leading to earlier 
presentation of diabetes25. It is possible there is a spe-
cific trigger that in MUO provokes faster aging. In line 
with our finding that the most significant decrease in 
HRV occurs during fourth decade of life, sarcopenia 
also begins in fourth decade, leading to metabolic 
stress and metabolic disorders26. It is possible that en-
largement of fat mass together with loss of muscle 
mass, which takes place from fourth decade of life 
(when autonomic decrease is notable), presents to-
gether with autonomic impairment associated with 
the aging process. Aging process is connected to meta-
bolic and fat mass distribution changes and insulin 
resistance. Based on these results, faster aging is con-
nected with autonomic decrease as well.
The exact mechanism how fat mass influences au-
tonomic functions is still not clear, but it is known that 
adipose cells are responsible for the secretion of adipo-
kines, e.g., leptin and adiponectin. Leptin is responsi-
ble for activation of neural signaling ways, which leads 
to sympathetic activity20. In old rats that were convert-
ed to metabolically ‘young’ profile using restrictive diet, 
leptin resistance could not be corrected. There is an 
age-dependent reinforcement of the blood-brain bar-
rier for leptin transmission. Age-dependent weaken-
ing of leptin transmission could be connected to lipo-
toxic and metabolic effects of age27. Leptin resistance 
could be connected with metabolic aging27. In the 
same way, increased cardiometabolic risk, insulin resis-
tance allied with autonomic neuropathy and ANS re-
sistance of MUO people could be connected with ear-
lier metabolic aging of the body.
For now, fourth decade of life appears to be the 
period of time when the autonomic-metabolic aging 
process starts manifesting its cardiac autonomic dys-
regulation in obese people. These circumstances pres-
ent themselves more prominently in MUO profiles. 
The results of this study point to the necessity of pre-
venting autonomic imbalance underlying obesity, early 
medication for metabolic changes and detection of 
 invisible complications in obesity, all in order to avoid 
premature aging.
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Sažetak
STARENJE, VARIJABILNOST SRČANE FREKVENCIJE I METABOLIČKI UTJECAJ PRETILOSTI
M. Rastović, B. Srdić-Galić, O. Barak, E. Stokić i S. Polovina
Dobne promjene u varijabilnosti srčane frekvencije (HRV) mogu zavisiti o metaboličkom profilu pretilih osoba, tj. me-
tabolički zdrave (MHO) i metabolički rizične pretile osobe (MUO). Željeli smo utvrditi dob u kojoj nastupa autonomna 
disfunkcija povezana s pretilošću te opada li HRV različito kod osoba različitog metaboličkog profila. Analizirali smo HRV 
kod 99 odraslih osoba uz primjenu Wildmanovih kriterija metaboličkog profila i HRV kao aktivnosti autonomnog živčanog 
sustava. Kod MHO, visoka frekvencija (HF) opadala je u 4. desetljeću života. Kod MUO su standardna devijacija svih R-R 
intervala (SDNN), kvadratni korijen srednje razlike između sukcesivnih normalnih R-R intevala (RMSSD), postotak suk-
cesivnih R-R intervala vrijednost kojih prelazi 50 ms (pNN50), HF, niska frekvencija (LF), omjer LF i HF (LF/HF) i 
 ukupna spektralna snaga (TP) opadali u 4. desetljeću života (parcijalna podijeljena varijanca 28%-36%). U zaključku, utvrđen 
je od dobi zavisan pad HRV kod MUO između trećeg i petog desetljeća života. Kod MHO osoba HF je značajno opala oko 
40. godine života. Kardiometabolički profil utječe na starenje remeteći funkcije autonomnog živčanog sustava.
Ključne riječi: Pretilost, metabolički benigna; Autonomni živčani sustav; Parasimpatički živčani sustav; Simpatički živčani 
sustav; Starenje; Srčana frekvencija
